Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ccm2tm1.1Etl mutation
(0 available);
any
Ccm2 mutation
(47 available)
|
|
|
mortality/aging
|
|
• embryonic lethality occurs between E9.5 and E10.5
|
embryo
|
|
• E9.5 homozygous embryos exhibit wrinkled yolk sacs
|
|
|
• E9.5 homozygous embryos can be distinguished from littermates due to their pale, wrinkled yolk sacs
|
cardiovascular system
|
|
• E9.5 embryos have delayed heart development with S-shaped tubes still present in some embryos
|
|
|
• E9.5 embryos suffer from pericardial edema
|
homeostasis/metabolism
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ccm2tm1.1Etl mutation
(0 available);
any
Ccm2 mutation
(47 available)
Ccm2tm1Etl mutation
(0 available);
any
Ccm2 mutation
(47 available)
Tg(Cdh5-cre/ERT2)1Rha mutation
(3 available)
|
|
|
mortality/aging
|
|
• mice injected with tamoxifen at P1 to induce recombination exhibit an median survival time of 17 days
|
cardiovascular system
|
|
• endothelial cell-cell junctions are altered in cerebellar vessels of mutants injected with tamoxifen at P1
• mice injected with tamoxifen at P1 do not exhibit increased endothelial cell proliferation at P6
|
|
|
• mice injected with tamoxifen at P1 develop cerebral cavernous malformation (CCM) lesions within the CNS beginning at P6
• CCM lesions that develop in mutants injected with tamoxifen affect the venous bed but not the arterial compartment
• mice injected with tamoxifen at 3 weeks of age do not exhibit any gross cerebrovascular phenotype, indicating that deletion of Ccm2 at three weeks of age does not lead to cerebral cavernous malformations
• fetuses at E19.5 of pregnant mice injected with tamoxifen at E14.5, exhibit vascular anomalies on the cerebral hemispheres with irregular and tortuous rhinal cerebral veins surrounded by abnormal capillaries
• mice injected with tamoxifen at P4 show a milder phenotype compared to tamoxifen treatment at P1, with single isolated caverns located within the cerebellum without sign of hemorrhage
|
|
|
• mice injected with tamoxifen at P1 show CCM vascular malformations at the periphery of the retinal vascular plexus in both eyes
• CCM malformations at the periphery of the retinas are restricted to veins and the surrounding capillaries
• mice injected with tamoxifen at P1 show a thicker vascular plexus at the venous leading edge of the retina at P7, with a 29% increase in vascular coverage compared to controls and dilated main veins by P9, with abnormal capillaries at the periphery of the vascular plexus
• by 3 weeks of age, mice injected with tamoxifen at P1 do not exhibit three distinguished vascular plexuses in the retinas as seen in controls, and the vasculature from the lesion is composed by bubble like vascular structures packed together
|
|
|
• cerebellar lesions of tamoxifen treated mice are composed of dilated vessels full of blood cells, and in severe cases there are signs of hemorrhage
• mice injected with tamoxifen at P1 exhibit dilation of vessels from the pial surface of the cerebellum and dilation of vessels running along the cerebellar folia at the meningeal surface corresponding to dorsal cerebellar veins
|
|
|
• extensive cerebral hemorrhages are seen mostly around the multiple caverns composing cerebral cavernous malformation lesions in mice before death
|
|
|
• fetuses at E19.5 of pregnant mice injected with tamoxifen at E14.5, exhibit hemorrhagic skin
|
nervous system
|
|
• mice injected with tamoxifen at P1 develop cerebral cavernous malformation (CCM) lesions within the CNS beginning at P6
• CCM lesions that develop in mutants injected with tamoxifen affect the venous bed but not the arterial compartment
• mice injected with tamoxifen at 3 weeks of age do not exhibit any gross cerebrovascular phenotype, indicating that deletion of Ccm2 at three weeks of age does not lead to cerebral cavernous malformations
• fetuses at E19.5 of pregnant mice injected with tamoxifen at E14.5, exhibit vascular anomalies on the cerebral hemispheres with irregular and tortuous rhinal cerebral veins surrounded by abnormal capillaries
• mice injected with tamoxifen at P4 show a milder phenotype compared to tamoxifen treatment at P1, with single isolated caverns located within the cerebellum without sign of hemorrhage
|
|
|
• extensive cerebral hemorrhages are seen mostly around the multiple caverns composing cerebral cavernous malformation lesions in mice before death
|
|
|
• mice injected with tamoxifen at P1 develop cerebral cavernous malformation lesions within the cerebellum beginning at P6
|
vision/eye
|
|
• mice injected with tamoxifen at P1 show CCM vascular malformations at the periphery of the retinal vascular plexus in both eyes
• CCM malformations at the periphery of the retinas are restricted to veins and the surrounding capillaries
• mice injected with tamoxifen at P1 show a thicker vascular plexus at the venous leading edge of the retina at P7, with a 29% increase in vascular coverage compared to controls and dilated main veins by P9, with abnormal capillaries at the periphery of the vascular plexus
• by 3 weeks of age, mice injected with tamoxifen at P1 do not exhibit three distinguished vascular plexuses in the retinas as seen in controls, and the vasculature from the lesion is composed by bubble like vascular structures packed together
|
integument
|
|
• fetuses at E19.5 of pregnant mice injected with tamoxifen at E14.5, exhibit hemorrhagic skin
|
Analysis Tools